Nemaura Medical touts improved sensor sensitivity, preps for UK SugarBeat clinical trial launch
Nemaura Medical said that the next-gen version of the sensor component of its SugarBeat non-invasive wireless skin patch has improved the device’s glucose detection by 300%, and announced the upcoming launch of a new clinical trial of the device.
The UK-based company’s SugarBeat CGM is designed as a wearable sensor patch which transmits data via bluetooth to provide real time glucose readings on a standalone reader, smart watch or smart phone app, the company said.
Nemaura said that the sensor improvements will allow users of the SugarBeat to detect small fluctuations in glucose levels and identify as it is able to detect glucose at very low levels.
The company said it will be launching a clinical trial program looking to track 75 patients over 525 days, with the study slated to commence “shortly” and an anticipated product launch before the end of this year.